ASEAN Business: 5 Biggest players in Thailand’s Pharmaceutical market when considering values or volumes reflect completely different profiles and segments

January 25, 2016

Pfizer, Novartis, MSD, Sanofi and Roche were top 5 big companies in Thailand by revenues in USD. While Novartis grew 15% thanks to its generics division and MSD had also a slight sales increase driven by its diabetes franchise, the rest experienced sales reduction in the period (Pfizer -2%, Sanofi -5% and Roche -7%). Considered as a segment, the Top 5 market share was reduced 0.3% in the period.


When looking at the sales in units, all companies except Roche experienced growth: Pfizer +3%, Novartis +21%, MSD +4%, Sanofi +3% (Roche -2%). The segment as a whole represents a little bit more than 5% and the market share grew 0.3% in the considered period.


Looking at the market in terms of volume, no one of the above mentioned companies would be placed among the top five: GPO, Otsuka, Thai Nakorn Patana, General Hospital and ANB would be there, with a combined market share of 32% (and a MS loss of 2% in the considered period). However, these five companies, four of them local, represent slightly more than 6% in values.


In summary, 5 international Top companies represent roughly ¼ of the market in values, although only 5% in units, while 4 local plus a Japanese one represent 1/3 of the market in volume and just 6% in values. This asymmetry should be taken into consideration when evaluating market potential, not only in Thailand but in most Emerging Markets

Please reload

Featured Posts

Top Pharmaceuticals are losing the battle in Emerging Markets and are generating an important slow-down effect in the market. Between 2012 to 2014 man...

Succeeding in Pharmaceutical Emerging Markets requires a different evaluation of Leadership Capabilities

January 27, 2016

Please reload

Recent Posts
Please reload

Please reload

Search By Tags
Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

© Copyright 2020 Emergpharma